Ghayas C. Issa, MD
Department of Leukemia, Division of Cancer Medicine
About Dr. Ghayas C. Issa
Dr. Issa is a clinical and translational researcher in the Departments of Leukemia and Genomic Medicine at the MD Anderson Cancer Center in Houston, Texas. His work focuses on the genetic underpinnings of leukemia to uncover therapeutic vulnerabilities, mechanisms of disease progression, and treatment response. Through this research, he aims to develop safe and effective targeted therapies.
His clinical research centers on menin inhibitors, a novel class of targeted therapies for acute leukemia. He serves as Principal Investigator on numerous investigator-initiated studies and multi-institutional clinical trials, which led to the FDA approval of the menin inhibitor revumenib for KMT2A-rearranged acute leukemia. He is also a lead investigator or steering committee member for global phase 3 trials evaluating menin inhibition in combination with standard of care for newly diagnosed acute myeloid leukemia. At MD Anderson, Dr. Issa leads a precision medicine program for acute leukemias susceptible to menin inhibition, focusing on biomarker discovery, measurable residual disease assays, resistance mechanisms, and rational combination therapies.
His research has been published in high-impact journals including Nature, New England Journal of Medicine, Cell, Journal of Clinical Oncology, Lancet Oncology, and Blood. Dr. Issa’s work has been recognized with numerous honors, including the ASCO Young Investigator Award, the TRTH Award from ASH and EHA, the Paul Calabresi K12 Award, the MD Anderson Faculty Scholar Award, and the Andrew Sabin Award.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Saint Joseph University Faculty of Medicine, Beirut, LB, MD |
| 2007 | Saint Joseph University Faculty of Medicine, Beirut, LB, Certificate in Immunology |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, Mount Sinai Beth Israel, New York, New York |
| 2010-2011 | Research Fellow, Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts |
Licenses & Certifications
| 2017 | American Board of Internal Medicine, Medical Oncology |
| 2017 | American Board of Internal Medicine, Hematology |
| 2014 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Other Professional Positions
Member, MD Anderson Cancer Center Support Grant Developmental Therapeutics Program (NCI), Houston, TX, 2023 - Present
Member, Global Steering Committee for the phase III Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients with Newly Diagnosed CML, Houston, TX, 2021 - Present
Member, Global Safety Monitoring Committee for the Phase 1 ziftomenib (KO-539) in combination, Houston, TX, 2013 - Present
Institutional Committee Activities
Member, Institutional Review Board 1, 2022 - Present
Member, Precision Oncology Decision Support team, 2022 - Present
Member, Academic Review Committee for the Division of Education & Training, 2022 - Present
Honors & Awards
| 2023 | Paper Selected for Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2018 | Paul Calabresi Clinical Oncology Award (K12), NIH |
| 2018 | Translational Research Training in Hematology Award, European Hematology Association and the American Society of Hematology |
| 2017 | The Kimberly Patterson Leukemia Research Fellowship, The University of Texas MD Anderson Cancer Center |
| 2017 | Future Leaders Award for Clinical Research in Hematology, Celgene |
| 2016 | Young Investigator Award, American Society of Clinical Oncology |
| 2016 | Molecular Biology in Clinical Oncology, 25th Annual AACR Workshop, American Association for Cancer Research |
| 2015 | Abstract Achievement Award,, American Society of Hematology |
| 2011 | Abstract Achievement Award, American Society of Hematology |
| 2008 | Scholar In Training Award, American Association for Cancer Research |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2023. The Future of Menin Inhibitors in AML. Conference. The Future of Menin Inhibitors in AML, US.
- 2023. Therapeutic Implications of Menin Inhibition. Conference. Therapeutic Implications of Menin Inhibition, US.
- 2023. Epigenetic targeting of leukemia using menin inhibitors. Conference. Epigenetic targeting of leukemia using menin inhibitors, US.
- 2023. Therapeutic Implications of Menin Inhibition. Conference. Therapeutic Implications of Menin Inhibition, US.
- 2023. Clinical Development in Rare Cancers: Menin Inhibitors. Conference. Clinical Development in Rare Cancers: Menin Inhibitors, US.
- 2022. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study. Conference. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study, US.
- 2022. Outcomes After Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions After Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience. Conference. Outcomes After Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions After Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience, US.
- 2017. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML. Conference. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia |
| Funding Source: | Kura Oncology |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Impact of Non-ABL Mutations on Outcomes of CML |
| Funding Source: | Scurlock Foundation |
| Role: | PI |
| ID: | 123515 |
| Date: | 2022 |
| Title: | Augment-102: a phase 1, open-label, dose-escalation study to evaluate safety, tolerability and preliminary anti-leukemic activity of SNDX-5613 in combination with chemotherapy in patients with relapsed/refractory leukemias harboring a KMT2A/MLL gene rearrangement or nucleophosmin 1 mutation (mnpm1) |
| Funding Source: | Syndax |
| Role: | PI |
| ID: | 14717 |
| Date: | 2022 - 2025 |
| Title: | A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) |
| Funding Source: | Astex Pharmaceuticals |
| Role: | PI |
| ID: | 14351 |
| Date: | 2022 - 2029 |
| Title: | A Phase 1, Open-label Study to Assess the Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered (14C)-SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemia |
| Funding Source: | Syndax |
| Role: | PI |
| ID: | 14220 |
| Date: | 2022 - 2027 |
| Title: | A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fmslike tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) |
| Funding Source: | Cullinan Florentine Corp |
| Role: | PI |
| ID: | 13360 |
| Date: | 2022 - Present |
| Title: | Single-cell Analysis in NUP98r Acute Leukemia |
| Funding Source: | Diego Osio-Llerenas Fund |
| Role: | PI |
| ID: | 1234304 |
| Date: | 2021 - 2028 |
| Title: | A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK-0482 in Participants with Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia |
| Funding Source: | Merck Sharp and Dohme Corp |
| Role: | PI |
| ID: | 13486 |
| Date: | 2021 - 2030 |
| Title: | A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 13913 |
| Date: | 2021 - 2024 |
| Title: | Eradicating Minimal Residual Disease in Chronic Myeloid Leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 12431 |
| Date: | 2021 - 2022 |
| Title: | Single-cell DNA/Protein Analysis (Mission Bio Tapestri) and CyTOF Monitoring of Menin Inhibition Clinical Trial |
| Funding Source: | Syndax |
| Role: | PI |
| Date: | 2020 - 2027 |
| Title: | A Phase 1/2A First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Funding Source: | Kura Oncology, Inc |
| Role: | PI |
| ID: | 11760 |
| Date: | 2020 - 2023 |
| Title: | Eradicating Minimal Residual Disease in Chronic Myeloid Leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Phase 1/2, Open-Label, Dose-Escalation and expansion cohort study of SNDX-5613 in Relapsed/refractory acute leukemia |
| Funding Source: | Syndax Pharma |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Start-up Funds |
| Funding Source: | MDACC |
| Role: | PI |
| Date: | 2020 - 2024 |
| Title: | Dual targeting of BCR-ABL in CML by adding the allosteric inhibitor ABL001 |
| Funding Source: | Novartis |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Investigating the Expression of the Luteinizing Hormone Receptor in the Hematopoietic Stem Cells of Patients with Leukemia |
| Funding Source: | Leukemia Texas |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Leukemia SPORE Career Development Award |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-P50-CA100632-15 |
| Date: | 2016 - 2018 |
| Title: | The Impact of Clonal Heterogeneity on Relapse after Hematopoietic Stem Cell Transplant in Patients with Acute Myeloid Leukemia |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Title: | A Multi-site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib |
| Funding Source: | Break Through Cancer, Syndax, Abbvie |
| Role: | PI |
| Title: | A Phase II Study of the Menin Inhibitor Revumenib in Acute Leukemia Associated with HOX gene Upregulation |
| Funding Source: | Syndax |
| Role: | PI |
| Title: | Refining precision medicine for menin-dependent acute leukemias |
| Funding Source: | Hyundai Hope On Wheels |
| Role: | PI |
| Title: | Investigating the Genomic and Epigenomic Mechanisms of Chronic Myeloid Leukemia Transformation from Chronic to Blast Phase |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | PI |
| ID: | Damon Runyon Physician-Scientist Training Award |
Selected Publications
Peer-Reviewed Articles
- Shi, X, Li, M, Liu, Z, Tiessen, J, Li, Y, Zhou, J, Zhu, Y, Mahesula, S, Ding, Q, Tan, L, Feng, M, Kageyama, Y, Hara, Y, Tao, JJ, Luo, X, Patras, KA, Lorenzi, PL, Huang, S, Stevens, A, Takahashi, K, Issa, GC, Samee, MH, Agathocleous, M, Nakada, D. Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40102405.
- Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- Haddad, FG, Sasaki, K, Senapati, J, Hu, S, Dellasala, S, Issa, GC, Jabbour, EJ, Kantarjian, HM. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma, Myeloma and Leukemia 25(4):254-257, 2025. e-Pub 2025. PMID: 39592322.
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
- Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
- Wei, Q, Toruner, GA, Thakral, B, Patel, KP, Pemmaraju, N, Wang, S, Kanagal Shamanna, R, Tang, G, Issa, GC, Loghavi, S, Medeiros, LJ, DiNardo, C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes 16(3), 2025. e-Pub 2025. PMID: 40149468.
- Jen, WY, Sasaki, K, Ravandi-Kashani, F, Kadia, TM, Wang, S, Wang, W, Loghavi, S, Daver, N, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Issa, GC, Aldoss, I, Thirman, MJ, DiPersio, JF, Arellano, M, Blachly, JS, Mannis, GN, Perl, AE, Dickens, DS, Mcmahon, C, Traer, E, Zwaan, CM, Grove, CS, Stone, RM, Shami, PJ, Mantzaris, I, Greenwood, M, Shukla, N, Cuglievan, B, Kovacsovics, T, Gu, Y, Bagley, RG, Madigan, K, Chudnovsky, Y, Van Nguyen, H, McNeer, N, Stein, EM. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology 43(1):75-84, 2025. e-Pub 2025. PMID: 39121437.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Wang, ES, Issa, GC, Erba, HP, Altman, JK, Montesinos, P, DeBotton, S, Walter, RB, Pettit, K, Savona, MR, Shah, MV, Kremyanskaya, M, Baer, MR, Foran, J, Schiller, GJ, Ades, L, Heiblig, M, Berthon, C, Peterlin, P, Rodríguez-Arbolí, E, Salamero, O, Patnaik, MM, Papayannidis, C, Grembecka, J, Cierpicki, T, Clegg, B, Ray, JM, Linhares, BM, Nie, K, Mitra, A, Ahsan, JM, Tabachri, M, Soifer, HS, Corum, D, Leoni, M, Dale, S, Fathi, AT. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001). The lancet oncology 25(10):1310-1324, 2024. e-Pub 2024. PMID: 39362248.
- McCall, DC, Abuasab, T, Rodriguez-Sevilla, JJ, Mohamed, SF, Patnaik, A, Devireddy, K, Arani, N, Sheikh, IN, Jamshidi, R, Gibson, A, Roth, M, Nunez, CA, Garcia, M, Chien, KS, Loghavi, S, Pierce, S, Sasaki, K, Issa, GC, Cuglievan, B, Kantarjian, H, Garcia-Manero, G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms. Leukemia Research 144, 2024. e-Pub 2024. PMID: 39178611.
- Sameeta, F, Fang, H, Wang, W, Tang, Z, Wang, S, Toruner, GA, Parisi, X, Khoury, J, Issa, GC, Garcia-Manero, G, Medeiros, LJ, Tang, G, Loghavi, S. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. American journal of hematology 99(9):1827-1829, 2024. e-Pub 2024. PMID: 38440855.
- Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
- Akiyama, H, Kantarjian, HM, Jabbour, EJ, Issa, GC, Haddad, FG, Short, NJ, Hu, S, Ishizawa, J, Andreeff, M, Sasaki, K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
- Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol 42(36):JCO2400272, 2024. e-Pub 2024. PMID: 39028925.
- Loghavi S, Wei Q, Ravandi F, Quesada AE, Routbort MJ, Hu S, Toruner GA, Wang SA, Wang W, Miranda RN, Li S, Xu J, DiNardo CD, Daver N, Kadia TM, Issa GC, Kantarjian HM, Medeiros LJ, Tang G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol 99(10):1959-1968, 2024. e-Pub 2024. PMID: 39016111.
- Issa GC, Stein EM, DiNardo CDD. How I Treat: Differentiation Therapy in Acute Myeloid Leukemia. Blood 145(12):1251-1259, 2024. e-Pub 2024. PMID: 38976876.
- Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5, 2024. e-Pub 2024. PMID: 38856690.
- Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, DiNardo CD, Rausch CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 130(11):1964-1971, 2024. e-Pub 2024. PMID: 38340331.
- Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
- Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
- Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med 391(10):885-898, 2024. e-Pub 2024. PMID: 38820078.
- Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, Cortes J, Nicolini FE, Issa GC, Jabbour E, Kantarjian H. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. e-Pub 2024. PMID: 38804723.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
- Issa GC. The development of menin inhibitors in AML and ALL. Clin Adv Hematol Oncol 22(4):185-187, 2024. e-Pub 2024. PMID: 38739722.
- Nasnas PE, Jabbour EJ, Sasaki K, Issa GC, Masarova L, Short NJ, Haddad FG. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia. Acta Haematol 148(1):105-110, 2024. e-Pub 2024. PMID: 38574468.
- Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
- Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Marvin-Peek, J, Sasaki, K, Kontoyiannis, DP, Adachi, JA, Ohanian, M, Takahashi, K, Issa, GC, Kornblau, SM, Abbas, HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia. Frontiers in Medicine 11, 2024. e-Pub 2024. PMID: 39149601.
- Sasaki, K, Haddad, FG, Short, NJ, Jain, N, Issa, GC, Jabbour, EJ, Kantarjian, HM. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
- Short, NJ, Muftuoglu, M, Ong, F, Nasr, L, Macaron, W, Montalban Bravo, G, Alvarado, Y, Basyal, M, Daver, N, DiNardo, C, Borthakur, G, Jain, N, Ohanian, M, Jabbour, EJ, Issa, GC, Qiao, W, Huang, X, Kanagal Shamanna, R, Patel, KP, Bose, P, Ravandi-Kashani, F, Delumpa, R, Abramova, R, Garcia-Manero, G, Andreeff, M, Cortes, JE, Kantarjian, HM. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1), 2023. e-Pub 2023. PMID: 37422688.
- Senapati, J, Muftuoglu, M, Ishizawa, J, Abbas, HA, Loghavi, S, Borthakur, G, Yilmaz, M, Issa, GC, Dara, S, Basyal, M, Li, L, Naqvi, K, Pourebrahim, R, Jabbour, EJ, Kornblau, SM, Short, NJ, Pemmaraju, N, Garcia-Manero, G, Ravandi-Kashani, F, Khoury, J, Daver, N, Kantarjian, HM, Andreeff, M, DiNardo, C. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37386016.
- Senapati, J, Urrutia, S, Loghavi, S, Short, NJ, Issa, GC, Maiti, A, Abbas, HA, Daver, N, Pemmaraju, N, Pierce, S, Chien, KS, Sasaki, K, Kadia, TM, Hammond, DE, Borthakur, G, Patel, KP, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, DiNardo, C. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Senapati, J, Fiskus, WC, Daver, N, Wilson, NR, Ravandi-Kashani, F, Garcia-Manero, G, Kadia, TM, DiNardo, C, Jabbour, EJ, Burger, JA, Short, NJ, Alvarado, Y, Jain, N, Masarova, L, Issa, GC, Qiao, W, Khoury, J, Pierce, SR, Miller, D, Sasaki, K, Konopleva, M, Bhalla, K, Borthakur, G, Pemmaraju, N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
- Sasaki, K, Morita, K, Kantarjian, HM, Garcia-Manero, G, Jabbour, EJ, Ravandi, F, Konopleva, M, Borthakur, G, Wierda, WG, Daver, N, Takahashi, K, DiNardo, C, Montalban Bravo, G, Issa, GC, Pierce, S, Soltysiak, KA, Tingen, MS, Cortes, JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma, Myeloma and Leukemia 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
- Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Haddad, FG, Sasaki, K, Bidikian, A, Issa, GC, Kadia, TM, Jain, N, Alvarado, Y, Short, NJ, Pemmaraju, N, Loghavi, S, Patel, KP, Kanagal Shamanna, R, Yilmaz, M, Masarova, L, Jabbour, EJ, Kantarjian, HM. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
- Gener-Ricos, G, Haddad, FG, Sasaki, K, Issa, GC, Skinner, J, Masarova, L, Borthakur, G, Alvarado, Y, Garcia-Manero, G, Jabbour, EJ, Kantarjian, HM. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
- Bazinet, A, Kantarjian, HM, Arani, N, Popat, U, Bataller, A, Sasaki, K, DiNardo, C, Daver, N, Yilmaz, M, Abbas, HA, Short, NJ, Issa, GC, Jabbour, EJ, Pierce, S, Chen, J, Garcia, R, Konopleva, M, Garcia-Manero, G, Alousi, A, Shpall, EJ, Champlin, RE, Borthakur, G, Ravandi-Kashani, F, Kadia, TM. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American journal of hematology 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
- Short, NJ, Jabbour, EJ, Macaron, W, Ravandi-Kashani, F, Jain, N, Kanagal Shamanna, R, Patel, KP, Loghavi, S, Haddad, FG, Yilmaz, M, Issa, GC, Kebriaei, P, Kornblau, SM, Pelletier, S, Flores, W, Matthews, JA, Garris, R, Kantarjian, HM. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. American journal of hematology 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
- Short, NJ, Ong, F, Ravandi, F, Nogueras Gonzalez, G, Kadia, TM, Daver, N, DiNardo, C, Konopleva, M, Borthakur, G, Oran, B, Al-Atrash, G, Mehta, RS, Jabbour, EJ, Yilmaz, M, Issa, GC, Maiti, A, Champlin, RE, Kantarjian, HM, Shpall, E, Popat, UR. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
- Trabal, AM, Gibson, A, He, J, McCall, DC, Roth, M, Nunez, CA, Garcia, MB, Buzbee, M, Toepfer, L, Bidikian, A, Daver, N, Kadia, TM, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garces, S, Marcogliese, A, Paek, H, Dreyer, Z, Brackett, J, Redell, MS, Yi, JS, Garcia-Manero, G, Konopleva, M, Stevens, A, Cuglievan, B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients. Cancers 15(7), 2023. e-Pub 2023. PMID: 37046645.
- Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, N, Garcia-Manero, G, Kadia, TM, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia 22:S233-S234, 2022. e-Pub 2022. PMID: 36163805.
- Hughes, TP, Cortes, JE, Takahashi, N, Larson, RA, Issa, GC, Bombaci, F, Ramscar, N, Kapoor, S, Ifrah, S, Hochhaus, A. CML-423 Trial in Progress. Clinical Lymphoma, Myeloma and Leukemia 22:S297-S298, 2022. e-Pub 2022. PMID: 36163929.
- Haddad, FG, Kantarjian, HM, Short, NJ, Konopleva, M, Jain, N, Huang, X, Ravandi-Kashani, F, Wierda, WG, Borthakur, G, Sasaki, K, Issa, GC, Alvarado, Y, Pemmaraju, N, Garcia-Manero, G, Thankachan, J, Garris, R, Jabbour, EJ. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S204, 2022. e-Pub 2022. PMID: 36163747.
- Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
- Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
- Levy, MY, Mauro, M, Issa, GC, Andorsky, D, Tomassetti, S, Broun, ER, Maegawa, RO, Deininger, M. CML-427 AIM4CML Trial in Progress. Clinical Lymphoma, Myeloma and Leukemia 22:S298, 2022. e-Pub 2022. PMID: 36163930.
- Bidikian, A, Kantarjian, HM, Jabbour, EJ, Short, NJ, Ravandi-Kashani, F, Issa, GC, Sasaki, K. CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S291, 2022. e-Pub 2022. PMID: 36163917.
Review Articles
- Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, Kadia, TM, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39300079.
- Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
- Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol 205(1):30-47, 2024. e-Pub 2024. PMID: 38724457.
- Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia 38(5):947-950, 2024. e-Pub 2024. PMID: 38531949.
- Senapati, J, Sasaki, K, Issa, GC, Lipton, JH, Radich, JP, Jabbour, EJ, Kantarjian, HM. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37088793.
Letters to the Editor
- Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
- Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
- Mustafayev, K, Yepez Guevara, E, DiNardo, CD, Jabbour, EJ, Issa, GC, Ratan, R, Pemmaraju, N, Torres, HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leukemia Research 147, 2024.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
- Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99: 1423-1426, 2024.
- Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk 24: 484-487, 2024.
- Haddad FG, Sasaki K, Issa GC, Jabbour E, Kantarjian H. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. Am J Hematol 99: 1175-1176, 2024.
- Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Bataller, A, Abuasab, T, McCall, DC, Wang, W, Cuglievan, B, Issa, GC, Jabbour, EJ, Short, NJ, DiNardo, C, Tang, G, Garcia-Manero, G, Kantarjian, HM, Sasaki, K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109: 293-297, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
- Haddad, FG, Bidikian, A, Issa, GC. Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia. Cancer.
Patient Reviews
CV information above last modified July 25, 2025